October 22, 2021
Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease
October 21, 2021
Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer
September 29, 2021
Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
August 23, 2021
Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer’s Disease Summit
August 16, 2021
Athira Pharma Reports Second Quarter 2021 Financial Results and Business Update
August 5, 2021
Athira Pharma Mourns the Loss of Chair of Board of Directors, Tadataka Yamada, M.D.
July 19, 2021
Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer’s Association International Conference 2021 (AAIC)
July 6, 2021
Athira Pharma Announces Initiation of Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of ATH-1017 for Alzheimer’s Disease
June 17, 2021
Athira Pharma Chief Operating Officer, Mark Litton, Assumes Day-to-Day Leadership Responsibilities of Company
June 14, 2021
Athira Pharma Appoints Rachel Lenington as Chief Technology Officer, Head of Product Development Strategy
Displaying 61 - 70 of 104